Evofosfamide

ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference

Retrieved on: 
Thursday, November 3, 2022
Society, PD-L1, Immunotherapy, PD-1, Patient, Cancer, Private Securities Litigation Reform Act, Evofosfamide, SITC, Poster, Pathology, Palladium, Vaccine

The posters will be available on the ImmunoGenesis website following the conference.

Key Points: 
  • The posters will be available on the ImmunoGenesis website following the conference.
  • The built-in engineered effector function allows IMGS-001 to kill immunosuppressive cells that express PD-L1 and/or PD-L2.
  • Preclinical data showed that IMGS-001 offered five times the response rate in cold tumors than currently available immunotherapies.
  • We may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.

Agenus Advances Portfolio with 6 Clinical Collaborations

Retrieved on: 
Tuesday, May 31, 2022
Cancer, Multiple myeloma, Company, Immunotherapy, Immunogenic cell death, Infection, GMP, U.S. Securities and Exchange Commission, KRAS, Tumor microenvironment, Patient, Prostate, EP4, NASDAQ, PD-1, Immunosuppression, Neelam, Agenus, Therapy, Clinical trial, Mink, TCR, Partnership, Ovarian cancer, Lung, Security (finance), Tumor hypoxia, Prostaglandin, Immune system, Twitter, Oxford, Annual report, Risk, Evofosfamide, GLOBE, Pharmaceutical industry, Vaccine

These 6 collaborations span a range of Agenus clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.

Key Points: 
  • These 6 collaborations span a range of Agenus clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.
  • The combination studies are being sponsored and executed by our collaborators, with drug supply and scientific support provided by Agenus.
  • This strategy, enabled by in-house integrated manufacturing and scientific capabilities, positions Agenus to achieve the insights and advances needed to drive development on accelerated timelines.
  • Agenus new and ongoing clinical collaborations are supporting and enabling:
    Targovax to conduct a clinical trial combining botensilimab and balstilimab with ONCOS-102 (oncolytic virus) in patients with PD-1 relapsed/refractory melanoma.

ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, "Cold" Cancers

Retrieved on: 
Tuesday, December 14, 2021
Cros, University of the Sciences, Cancer, Doctor of Philosophy, Private Securities Litigation Reform Act, PPD, Inc., Industry, Kohlberg Kravis Roberts, Health policy, Drug, CEO, GSK, Patient, University, Neoplasm, Pathology, Evofosfamide, Program, Poznań University of Medical Sciences, CRO, Pharmaceutical industry, Medical imaging, Pharmacy, Eisai, Science

Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations (CROs), including most recently as Therapeutic Area Head of Oncology at GSK.

Key Points: 
  • Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations (CROs), including most recently as Therapeutic Area Head of Oncology at GSK.
  • In his new ImmunoGenesis role, he will drive clinical development strategy and operational execution as the company prepares to initiate multiple clinical trials in 2022.
  • "Dr. Schweizer's deep oncology clinical development and operations experience will power our strategy and vision for clinical development of our therapy candidates targeting immune-excluded, cold tumors where existing immunotherapies are not effective.
  • As the head of clinical product development, he was responsible for clinical and regulatory strategy, operational execution, and cross-functional alignment of the clinical pipeline at all development stages.

Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference

Retrieved on: 
Monday, November 15, 2021
Evofosfamide, Ipilimumab, Efficiency, NFAT, Hypoxia, SITC, PD-L1, Tumor hypoxia, Private Securities Litigation Reform Act, Neoplasm, Prostate cancer, CEO, PD-L2, RNA, Society, Growth, Syngenic, Microglia, Immunotherapy, Tumor microenvironment, PD-1, Program, Cancer, Rituximab, MDSC, Cadence, DC101, Antibody, Therapy, ADCC, Mouse, Pathology, Survival, CDN, Patient, Immunosuppression, FDA, M1, Glioblastoma, Pharmaceutical industry, Palladium, Vaccine, Medical imaging

The preclinical results presented advance the development of ImmunoGenesis' immunotherapy programs.

Key Points: 
  • The preclinical results presented advance the development of ImmunoGenesis' immunotherapy programs.
  • "We are very pleased to have data from our programs presented at SITC," said James Barlow , ImmunoGenesis President and CEO.
  • "These strong study findings support our development programs focused on creating therapies that target cold cancersincluding pancreatic cancersrefractory to currently available immunotherapy.
  • Put together, these data indicate that targeted reduction of hypoxia with anti-angiogenic therapy remodels the tumor microenvironment and enhances immunotherapy responses in PDAC.

ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals

Retrieved on: 
Tuesday, August 31, 2021
Journal, Private Securities Litigation Reform Act, American Association for Cancer Research, Human, Texas, Glioblastoma, PD-1, Nucleic acid metabolism, Myc, Veterinary medicine, Clinical Cancer Research, Stimulator of interferon genes, Research, Tumor microenvironment, American Association, Joan, National, PDAC, Immunotherapy, Biomedical sciences, Immune privilege, GBM, Patient, CEO, MRI, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Dog, Neoplasm, Association, Pancreatic cancer, Injection, CDG, Evofosfamide, Vaccine, Beekeeping

Further, data revealed that intratumoral injection of ImmunoGenesis' STING agonist into orthotopic pancreatic lesions unmasks sensitivity to checkpoint blockade, further indicating the potential of its STING agonist to help overcome immunotherapy resistance in cold tumors.

Key Points: 
  • Further, data revealed that intratumoral injection of ImmunoGenesis' STING agonist into orthotopic pancreatic lesions unmasks sensitivity to checkpoint blockade, further indicating the potential of its STING agonist to help overcome immunotherapy resistance in cold tumors.
  • "These two published studies show strong preclinical proof of concept of our STING agonist against cold cancersincluding pancreatic and brain cancersrefractory to currently available immunotherapy," said James Barlow , ImmunoGenesis President and CEO.
  • "This further reveals the potential for ImmunoGenesis' STING agonist to be a foundational treatment in immunologically resistant cancers such as GBM."
  • The investigators tested the STING agonist by injection directly into the glioblastoma of five dogs that had previously been diagnosed with the cancer.

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Retrieved on: 
Monday, June 21, 2021
Neoplasms, Sarcoma, Clinical medicine, Anatomical pathology, Soft-tissue sarcoma, Acute myeloid leukemia, Evofosfamide

Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.

Key Points: 
  • Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
  • Soft tissue sarcomas are the most common form of sarcoma, accounting for an estimated 130,000 incident cases per year worldwide.
  • For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

ImmunoGenesis Announces Publication of Phase 1 Data on its Hypoxia-Reversal Agent Highlighting Efficacy and Genetic Expression Correlatives in Advanced Cancer

Retrieved on: 
Wednesday, June 16, 2021
Clinical medicine, Medicine, Cancer, Cancer immunotherapy, Oncology, Virotherapy, Bristol-Myers Squibb, Ipilimumab, Prostate cancer, Immunotherapy, Checkpoint inhibitor, Evofosfamide

"A hostile tumor metabolism is a major source of immune resistance in certain tumors,"said James Barlow , ImmunoGenesis President and CEO.

Key Points: 
  • "A hostile tumor metabolism is a major source of immune resistance in certain tumors,"said James Barlow , ImmunoGenesis President and CEO.
  • "Evofosfamide, with the demonstrated ability to reduce tumor hypoxia, can be a critical component of facilitating immunotherapy efficacy in these tumors.
  • "These exciting Phase 1 data support preclinical observations in which evofosfamide reversed tumor hypoxia and facilitated the efficacy of checkpoint inhibition.
  • The Phase 1 (NCT03098160), dose-escalation study tested evofosfamide in combination with ipilimumab administered in four three-week cycles inheavily pre-treated patients with castration-resistant prostate cancer, advanced pancreatic cancer, immunotherapy-resistant melanoma, and advanced HPV-negative head and neck cancer.

Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas

Retrieved on: 
Wednesday, June 9, 2021
Research, Pharmaceutical, Oncology, Technology, Infectious diseases, Genetics, Clinical trials, Science, Nanotechnology, Biotechnology, FDA, Health, Other Science, Health sciences, Health, Clinical research, Pharmaceutical industry, Medical research, Clinical trial, ClinicalTrials.gov, Adverse event, Evofosfamide, Tecemotide

The 6-month trial enrolled 19 subjects and was completed in late 2020.

Key Points: 
  • The 6-month trial enrolled 19 subjects and was completed in late 2020.
  • The clinical study report was submitted to FDA in April 2021 and clinical trial results can be found at NCT03188991 in clinicaltrials.gov.
  • Overall, the drug was well tolerated with no dose limiting toxicities or drug-related significant adverse events observed.
  • In addition to this trial, NanOlogys clinical programs are advancing in pancreatic, lung, genitourinary, and dermal cancers.

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Alcohols, Carbonyl compounds, Drugs, Orphan drugs, Breast cancer, Protein-bound paclitaxel, Paclitaxel, Gemcitabine, Pancreatic cancer, Evofosfamide

The conclusion of theposter is that SBP-101 may enhance first-line treatment with gemcitabine and nab-paclitaxel patients with metastatic PDA.

Key Points: 
  • The conclusion of theposter is that SBP-101 may enhance first-line treatment with gemcitabine and nab-paclitaxel patients with metastatic PDA.
  • We look forward to initiating a randomized phase 2 study in metastatic PDA mid-year.
  • In the response-evaluable subjects in cohort 4 + Phase 1b (N=29), 11 had treatment with SBP-101 interrupted to evaluate retinal toxicity; this may impact final efficacy results.
  • SBP-101 was well-tolerated when administered at doses and schedules tested in combination with G+A in subjects with previously untreated metastatic pancreatic adenocarcinoma.

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

Retrieved on: 
Friday, June 4, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Cancer, Pancreatic cancer, Clinical medicine, Health, Neuroendocrine tumor, Neuroendocrinology, Endocrine oncology, Pancreatic neuroendocrine tumor, Somatostatin receptor 2, Evofosfamide, PEN-221, Tarveda Therapeutics®, Inc., PEN-221, TARVEDA THERAPEUTICS®, INC.

Gastrointestinal neuroendocrine tumors are a disease with a significant unmet need.

Key Points: 
  • Gastrointestinal neuroendocrine tumors are a disease with a significant unmet need.
  • This approach demonstrated encouraging efficacy results in the GI mid-gut NET cohort of the Phase 2 trial and was well tolerated by patients.
  • SSTR2 is overexpressed on the cell surface of a range of solid tumors including neuroendocrine tumors and small cell lung cancers.
  • PEN-221 is being evaluated in Phase 2a expansion cohorts enrolling patients with mid-gut neuroendocrine tumors, pancreatic neuroendocrine tumors, and small cell lung cancer (ClinicalTrials.gov Identifier: NCT02936323 ).